RxDoctor Payments DataLook up a doctor →

Reynold Panettieri, MD

Pulmonary Disease · New Brunswick, NJNPI 1104830629

Payments from drug & device makers

$2,519,745in general payments, 2019–2025

Across 796 payments — averaging $3165.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$824K
  • AstraZeneca$753K
  • Astrazeneca AB$227K
  • Genentech, Inc.$210K
  • Regeneron Healthcare Solutions, Inc.$165K
  • Sanofi$107K
  • plus $233K from 15 others
$1,997in research payments, 2019–2025

Across 4 payments — averaging $499.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi-aventis U.S. LLC$1K
  • Sanofi$750

What the payments were for

  • Consulting fees$311,03031%
  • Speaking & faculty fees$596,08959%
  • Grants$3,0000%
  • Travel & lodging$85,6478%
  • Food & beverage$14,1721%
  • Education$570%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,519,745 in reported general payments places this provider in the 95th percentile of 472 pulmonary disease providers in New Jersey.

See all pulmonary disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$20,208
Medicare patients
20
Services billed
560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TezspireTezepelumab-Ekko27$130,689
Fasenra PenBenralizumab21$121,705
Dupixent PenDupilumab12$51,573
Spiriva RespimatTiotropium Bromide25$16,799
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate20$7,400
SymbicortBudesonide/Formoterol Fumarate15$6,321
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$4,962
DuleraMometasone/Formoterol11$3,944
Advair HfaFluticasone Propion/Salmeterol12$3,385
BreynaBudesonide/Formoterol Fumarate12$2,550
Albuterol Sulfate HfaAlbuterol Sulfate41$1,360
Zafirlukast11$549
Roflumilast11$547
Azithromycin24$464
Fluticasone Propionate19$350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTezspire, Symbicort$753,404$137,01042 claims
Boehringer IngelheimSpiriva Respimat$7,100$16,79925 claims
MerckDulera$13,849$3,94411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 472 pulmonary disease providers in New Jersey.

Other pulmonary disease in New Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →